Losers at NASDAQ: Mandalay Digital Group (NASDAQ:MNDL), Dixie Group Inc (NASDAQ:DXYN), Oncothyreon (NASDAQ:ONTY), Astrotech (NASDAQ:ASTC), LiveDeal (NASDAQ:LIVE)

Mandalay Digital Group, Inc. (NASDAQ:MNDL), a leading provider of mobile technology solutions, announced on 02 June 2014 that it has expanded its relationship with SingTel to include direct billing connectivity with its DT Pay product. Mandalay Digital Group Inc (NASDAQ:MNDL) stock performance was -5.32% in last session and finished the day at $3.56. Traded volume was 203,024.00million shares in the last session and the average … Continue reading Losers at NASDAQ: Mandalay Digital Group (NASDAQ:MNDL), Dixie Group Inc (NASDAQ:DXYN), Oncothyreon (NASDAQ:ONTY), Astrotech (NASDAQ:ASTC), LiveDeal (NASDAQ:LIVE)

Healthcare Watch List: Oncothyreon (NASDAQ:ONTY), Corcept Therapeutics Incorporated (NASDAQ:CORT), Aastrom Biosciences (NASDAQ:ASTM), Durata Therapeutics (NASDAQ:DRTX)

Corcept Therapeutics (NASDAQ:CORT) Director Longitude Venture Partners L.P sold 250,000 shares of the company’s stock on the open market in a transaction dated Friday, May 2nd. The stock was sold at an average price of $4.11, for a total value of $1,027,500.00. Corcept Therapeutics Incorporated (NASDAQ:CORT) rose 5.06% percent to $ 4.15 yesterday on volume of 319,314 shares. The intra-day range of the stock was … Continue reading Healthcare Watch List: Oncothyreon (NASDAQ:ONTY), Corcept Therapeutics Incorporated (NASDAQ:CORT), Aastrom Biosciences (NASDAQ:ASTM), Durata Therapeutics (NASDAQ:DRTX)

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported a fourth-quarter 2013 loss of 32 cents per share (excluding one-time expenses), narrower than the year-ago loss of 43 cents per share and the Zacks Consensus Estimate of a loss of 40 cents. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock performance was -6.08% in last session and finished the day at $1.70. Traded volume was 1.35million shares in the last session and … Continue reading Top Losers: AVEO Pharmaceuticals (NASDAQ:AVEO), Santander Mexico Fincl Gp SAB (NYSE:BSMX), Oncothyreon Inc (NASDAQ:ONTY), Omeros Corporation (NASDAQ:OMER)

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor Inc. (NASDAQ:XNCR) stock performance was -1.58% in last session and finished the day at $13.68. Traded volume was 99,904.00 shares … Continue reading Biotech Overbought Socks: Xencor Inc. (NASDAQ:XNCR), Albany Molecular Research (NASDAQ:AMRI), Oncothyreon (NASDAQ:ONTY), OXiGENE Inc. (NASDAQ:OXGN)

4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its full year and fourth quarter 2013 financial results and provide a review of its pipeline of products in development. Oncothyreon Inc. (USA) (NASDAQ:ONTY) stock performance was 1.92% in last session and finished the day at $3.72. Traded volume was 1.16 million shares in the last session and the average volume of the stock remained 904,463.00 … Continue reading Biotech Stocks Touching New Highs: Oncothyreon (NASDAQ:ONTY), IGI Laboratories (NYSEMKT:IG), TG Therapeutics (NASDAQ:TGTX), Receptos Inc. (NASDAQ:RCPT)

Equities research analysts at Deutsche Bank assumed coverage on shares of Arrowhead Research Corp (NASDAQ:ARWR) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $45.00 price target on the stock. Arrowhead Research Corp (NASDAQ:ARWR) stock performance was 24.46% in last session and finished the day at $26.31. Traded volume was 7,684,553 million shares in the … Continue reading Biotech Gainers: Arrowhead Research (NASDAQ:ARWR), DARA Biosciences (NASDAQ:DARA), Synthetic Biologics (NYSEMKT:SYN), Oncothyreon (NASDAQ:ONTY)